US12599620B2 - Chronic Fatigue Syndrome Plasma Cell Inhibitor Treatment Method
Summary
The USPTO granted Patent US12599620B2 to Vestlandets Innovasjonsselskap AS covering a method for treating chronic fatigue syndrome using inhibitory or cytotoxic agents against plasma cells. The patent also claims combinations of plasma cell-targeting agents with B-cell depleting agents or B-cell activation inhibitors. The patent application was filed on August 31, 2020, under application number 17638453, and contains 3 claims.
What changed
The USPTO granted patent protection for a therapeutic method using inhibitory or cytotoxic agents against plasma cells for the treatment of chronic fatigue syndrome. The patent also covers combination therapies pairing plasma cell inhibitors with B-cell depleting agents or B-cell activation inhibitors, as well as kit formulations containing these compounds in therapeutically effective dosages.
Patent holders and licensees gain exclusive rights to commercialize these CFS treatment methods in the United States. Pharmaceutical companies and medical researchers should review freedom-to-operate positions before developing competing plasma cell-targeted therapies for CFS. The patent's broad claims covering both singular and combination approaches may constrain development paths in this therapeutic area.
What to do next
- Monitor FDA requirements for downstream drug development approvals
Archived snapshot
Apr 15, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method for the treatment of chronic fatigue syndrome using an inhibitory or cytotoxic agent against plasma cells
Grant US12599620B2 Kind: B2 Apr 14, 2026
Assignee
Vestlandets Innovasjonsselskap AS
Inventors
Øystein Fluge, Olav Mella
Abstract
The present disclosure relates in a first aspect to a method for the treatment of chronic fatigue syndrome (CFS) comprising administering to a patient in need thereof a therapeutically effective amount of inhibitory or cytotoxic agent against plasma cells. In a further aspect, the present disclosure relates to a combination of the inhibitory or cytotoxic agent against plasma cells with a B-cell depleting agent or an inhibitor of B-cell activation in the treatment of chronic fatigue syndrome. In addition, a combination of an inhibitory or cytotoxic agent against plasma cells and B-Cell depleting agent or an inhibitor of B-cell activation are described. Said combination may be provided in form of a kit comprising suitably effective dosages of said compounds. Further, the use of the compounds or the combination in the treatment of CFS is described.
CPC Classifications
A61K 31/69 A61K 31/407 A61K 38/06 A61K 38/07 A61K 39/3955 A61K 2039/507 A61K 2039/545 A61K 2039/505 A61K 9/0019 A61K 31/675 A61K 38/05 A61K 45/06 A61K 40/4222 A61P 25/00 C07K 16/2887 G01N 2800/306
Filing Date
2020-08-31
Application No.
17638453
Claims
3
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.